189 related articles for article (PubMed ID: 22675167)
1. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
[TBL] [Abstract][Full Text] [Related]
2. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
5. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
6. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
[TBL] [Abstract][Full Text] [Related]
7. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
8. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
Best OG; Gardiner AC; Majid A; Walewska R; Austen B; Skowronska A; Ibbotson R; Stankovic T; Dyer MJ; Oscier DG
Leukemia; 2008 Jul; 22(7):1456-9. PubMed ID: 18200038
[No Abstract] [Full Text] [Related]
9. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
10. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
[TBL] [Abstract][Full Text] [Related]
11. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
12. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA
BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021
[TBL] [Abstract][Full Text] [Related]
13. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
14. A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity.
Kabacik S; Ortega-Molina A; Efeyan A; Finnon P; Bouffler S; Serrano M; Badie C
Cell Cycle; 2011 Apr; 10(7):1152-61. PubMed ID: 21389785
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].
Yu GZ; Zhu MH; Chen Y; Ni CR; Li FM
Ai Zheng; 2005 Nov; 24(11):1398-403. PubMed ID: 16552971
[TBL] [Abstract][Full Text] [Related]
17. The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function.
Lo PK; Lee JS; Sukumar S
Cell Signal; 2012 Jan; 24(1):316-24. PubMed ID: 21964066
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
[TBL] [Abstract][Full Text] [Related]
19. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky D; Richards S; Matutes E; Oscier D; Dyer M; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P; ;
Lancet; 2007 Jul; 370(9583):230-239. PubMed ID: 17658394
[TBL] [Abstract][Full Text] [Related]
20. [Interaction between ATM and radiation-activated phosphorylation of P53 and P21].
Luo JL; Cao JP; Zhu W; Feng S; Sheng FJ; Zhu CY; Zheng SY
Ai Zheng; 2005 Sep; 24(9):1059-63. PubMed ID: 16159425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]